HIV type 1 polymerase gene polymorphisms are associated with phenotypic differences in replication capacity and disease progression

Journal of Infectious Diseases

Volumn 209, Issue 1, 2014, Pages 66-73

  Ng, Oon Tek ^a,f   Laeyendecker, Oliver ^a,c   Redd, Andrew D ^c   Munshaw, Supriya ^a   Grabowski, Mary K ^b   Paquet, Agnes C ^e   Evans, Mark C ^e   Haddad, Mojgan ^e   Huang, Wei ^e   Robb, Merlin L ^d   Reynolds, Steven J ^a,c   Gray, Ronald H ^b   Wawer, Maria J ^b   Serwadda, David ^g   Eshleman, Susan H ^a   Quinn, Thomas C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e MONOGRAM BIOSCIENCES   (United States)

^f TAN TOCK SENG HOSPITAL   (Singapore)

^g MAKERERE UNIVERSITY   (Uganda)

Author keywords

amino acid polymorphisms; disease progression; HIV 1 Subtype; polymerase; replication capacity; subtype A; subtype D

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED DNA POLYMERASE DELTA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE COURSE; DNA HYBRIDIZATION; DNA POLYMORPHISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SEROCONVERSION; UGANDA; VIRUS REPLICATION;

AMINO ACID POLYMORPHISMS; DISEASE PROGRESSION; HIV-1 SUBTYPE; POLYMERASE; REPLICATION CAPACITY; SUBTYPE A; SUBTYPE D;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; DISEASE PROGRESSION; FEMALE; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; UGANDA; VIRAL LOAD; VIRUS REPLICATION;

EID: 84891357006     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit425     Document Type: Article

References (25)

1. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-89.
2. Los Alamos Security. HIV databases. 2012. http://www.hiv.lanl.gov/. Accessed 13 March 2013.
3. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-80.
4. Keller M, Lu Y, Lalonde RG, Klein MB. Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS 2009; 23:731-7.
5. Ng OT, Lin L, Laeyendecker O, et al. Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01-AE infected seroconverters in Singapore. PLoS One 2011; 6: e15738.
6. Nelson KE, Costello C, Suriyanon V, Sennun S, Duerr A. Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A-E) infection in northern Thailand, 1992-2007. AIDS 2007; 21 Suppl 6: S47-54.
7. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-13.
8. Daar ES, Kesler KL, Petropoulos CJ, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643-9.
9. Learmont JC, Geczy AF, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999; 340:1715-22.
10. Barbour JD, Hecht FM, Wrin T, et al. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004; 190:251-6.
11. Goetz MB, Leduc R, Wyman N, et al. HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 2010; 53:472-9.
12. Kiwanuka N, Robb M, Kigozi G, et al. Knowledge about vaccines and willingness to participate in preventive HIV vaccine trials: a population-based study, Rakai, Uganda. J Acquir Immune Defic Syndr 2004; 36:721-5.
13. Eshleman SH, Laeyendecker O, Parkin N, et al. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009; 23:845-52.
14. Hoelscher M, Dowling WE, Sanders-Buell E, et al. Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multiregion hybridization assay. AIDS 2002; 16:2055-64.
15. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-8.
16. Choe SS, Stawiski E, Parkin NT. Interpretation of drug-susceptibility and replication-capacity results from subtype C HIV-1 Protease/RT is not influenced by the subtype of the resistance test vector. Antivir Ther 2007; 12:S118.
17. Kiwanuka N, Robb M, Laeyendecker O, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr 2010; 54:180-4.
18. Institute for Statistic and Mathematics. The R project for statistical computing. 2012. http://www.r-project.org. Accessed 4 February 2013.
19. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008; 8:619-30.
20. Yue L, Prentice HA, Farmer P, et al. Cumulative impact of host and viral factors on HIV-1 viral load control during early infection. J Virol 2013; 87:708-15.
21. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944-7.
22. Prince JL, Claiborne DT, Carlson JM, et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog 2012; 8:e1003041.
23. Parera M, Fernandez G, Clotet B, Martinez MA. HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol 2007; 24:382-7.
24. Cabana M, Fernandez G, Parera M, Clotet B, Martinez MA. Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions. Virology 2002; 300:71-8.
25. Redd AD, Laeyendecker O, Kong X, et al. Efficiency of CCR5 coreceptor utilization by the HIV quasispecies increases over time, but is not associated with disease progression. AIDS Res Hum Retroviruses 2012; 28:289-94.